When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Olaparib - Wikipedia

   en.wikipedia.org/wiki/Olaparib

   In January 2018, olaparib was approved in the United States for the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any ...

3. PARP inhibitor - Wikipedia

   en.wikipedia.org/wiki/PARP_inhibitor

   Pamiparib (BGB-290) For ovarian cancer, 1st patient enrolled May 2018. [30] It is a PARP1 and PARP2 inhibitor. [31] [32] Started Phase II: Olaparib (developed by AstraZeneca) for breast, ovarian and colorectal cancer. [33] [34] Olaparib TOPARP-A trial for use in advanced prostate cancer (published c. April 21, 2015). [35]

4. Cancer treatment - Wikipedia

   en.wikipedia.org/wiki/Cancer_treatment

   Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]

5. List of unproven and disproven cancer treatments - Wikipedia

   en.wikipedia.org/wiki/List_of_unproven_and...

   A review by the Memorial Sloan Kettering Cancer Center found no evidence that the Hoxsey Therapy was effective as a treatment for cancer. [48] Issels treatment – a regime recommended to be used alongside conventional treatment. It requires removal of metal fillings from the patient's mouth, and adherence to a restrictive diet.

6. Targeted therapy - Wikipedia

   en.wikipedia.org/wiki/Targeted_therapy

   There are targeted therapies for lung cancer, colorectal cancer, head and neck cancer, breast cancer, multiple myeloma, lymphoma, prostate cancer, melanoma and other cancers. [1] [4] [5] Biomarkers are usually required to aid the selection of patients who will likely respond to a given targeted therapy. [6]

7. Rucaparib - Wikipedia

   en.wikipedia.org/wiki/Rucaparib

   After the FDA approval, TRITON2 and TRITON3 mCRPC studies were initiated in order to determine how patients with prostate cancer will respond to the rucaparib drug. The studies for these two trials are still going on and the estimated dates for the first results are range between 2019 and 2022. [14]